AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26631691
Drug: Oral moisturizing
RxNorm normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral moisturizing jelly (OMJ) used for 2 weeks
Trial: 26631691
Drug: Oral moisturizing
RxNorm normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral moisturizing jelly (OMJ) used for 1 month
Trial: 26632544
Drug: other treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: other treatments
Trial: 26632544
Drug: antiviral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antiviral treatment
Trial: 26632544
Drug: nutritional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nutritional treatment
Trial: 26632545
Drug: Immunotherapy strategies
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy strategies including vaccines, adaptive therapy, immune checkpoint blockades, and cytokines.
Trial: 26632880
Drug: Chemotherapy-induced pain
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy-induced pain (CHIP)
Trial: 26635965
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention followed by standard fertility treatments after 6 months if no conception has been achieved
Trial: 26635965
Drug: Standard fertility
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard fertility treatments only
Trial: 26637464
Drug: Artemisinin combination
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin combination therapies (ACTs) during early pregnancy
Trial: 26637464
Drug: Pregnant women
RxNorm normalized name: Hydroxyprogesterone Caproate 250mg/1mL Solution for injection [For Non-pregnant Women]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnant women treated for malaria but exposed to other antimalarials
Trial: 26639348
Drug: Venetoclax (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (150 to 1200 mg per day in dose-escalation phase; up to 400 mg per day in expansion cohort)
Trial: 26639348
Drug: Venetoclax (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (400 mg per day)
Trial: 26639404
Drug: Vector insertion
RxNorm normalized name: Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vector insertion sites (VIS) in iC9-T cells pre- and post-CID administration.
Trial: 26640039
Drug: Ibrutinib (560
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib (560 mg daily) combined with Rituximab (375 mg/m2 IV once per week for 4 weeks, then on day 1 of cycles 3-8, and thereafter once every other cycle up to 2 years)
Trial: 26640780
Drug: Anti-CEA × anti-histamine-succinyl-glycine (HSG)-humanized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CEA × anti-histamine-succinyl-glycine (HSG)-humanized trivalent bispecific antibody (TF2) and IMP288 bivalent HSG peptide
Trial: 26640780
Drug: TF2 pharmacokinetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TF2 pharmacokinetics (PK)
Trial: 26640780
Drug: (111)In- and
RxNorm normalized name: metformin and ertugliflozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (111)In- and (177)Lu-IMP288 pharmacokinetics (PK)
Trial: 26641137
Drug: Acalabrutinib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acalabrutinib (100 to 400 mg once daily in phase 1, 100 mg twice daily in phase 2)
Trial: 26643737
Drug: Successful drug-eluting
RxNorm normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful drug-eluting stent implantation
Trial: 26645405
Drug: Carboplatin administered
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin administered intravenously for 60 min after blood-brain barrier disruption using an implantable ultrasound device.
Trial: 26645894
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment in early life
Trial: 26646829
Drug: Ultra-low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low dose IL-2
Trial: 26646829
Drug: Initial learning
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial learning phase with six different doses and frequencies of IL-2
Trial: 26647281
Drug: DC-based vaccine
RxNorm normalized name: covid-19, RNA-based vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC-based vaccine loaded with autologous HIV-1-infected apoptotic cells
Trial: 26648747
Drug: Olaparib maintenance
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib maintenance therapy (placebo-controlled)
Trial: 26649075
Drug: MBP-NC (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBP-NC (200 mg red yeast rice extract, 500 mg berberine, 10 mg policosanols)
Trial: 26649337
Drug: Contrast enhanced
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast enhanced ultrasound (CEUS) with 2.4 ml SonoVue
Trial: 26649807
Drug: Cetuximab combined
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab combined with docetaxel (weekly cetuximab: first infusion 400 mg/m², then 250 mg/m²; docetaxel: 100 mg/m² every 3 weeks)
Trial: 26650227
Drug: BI 847325
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 847325 (Schedule A, 2 weeks on, 1 week off, starting at 6 mg, MTD 120 mg/day)
Trial: 26650227
Drug: BI 847325
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 847325 (Schedule B, three periods of 5 days on, 2 days off, MTD 150 mg/day)
Trial: 26652184
Drug: Dendritic cell
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dendritic cell vaccination combined with low-dose cyclophosphamide
Trial: 26653754
Drug: Opioid substitution
RxNorm normalized name: hydroxypropyl cellulose, low substituted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid substitution therapy
Trial: 26654630
Drug: Plasma exchange/plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma exchange/plasma infusion
Trial: 26655846
Drug: PF-03446962 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-03446962 (10 mg/kg, recommended phase II dose 7 mg/kg)
Trial: 26655846
Drug: PF-03446962 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-03446962 (0.5 to 15 mg/kg)
Trial: 26656277
Drug: QLT091001 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QLT091001 (40 mg/m2/day for 7 days)
Trial: 26656373
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Shapiro score with PCT levels
Trial: 26656373
Drug: Shapiro score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shapiro score ≥4 or PCT > 0.1 μg/L
Trial: 26656373
Drug: Shapiro score
RxNorm normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shapiro score ≥3 or PCT >0.25 μg/L
Trial: 26663671
Drug: Automatic Stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automatic Stimulation Mode (AutoStim) of the Model 106 Vagus Nerve Stimulation (VNS) Therapy System
Trial: 26663719
Drug: Docetaxel 40
RxNorm normalized name: docetaxel 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 40 mg/m² for Category 1 patients
Trial: 26663719
Drug: Docetaxel 30
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 30 mg/m² for Category 2 patients
Trial: 26663719
Drug: Docetaxel 20
RxNorm normalized name: docetaxel 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 20 mg/m² for Category 3 patients
Trial: 26666244
Drug: Selumetinib 75
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib 75 mg p.o. BID and cetuximab 250 mg/m(2) weekly following a 400 mg/m(2) load
Trial: 26666244
Drug: Selumetinib and
RxNorm normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib and cetuximab combination
Trial: 26666256
Drug: New and
RxNorm normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 27 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 50 mg in 1 mL TOPICAL LOTION [Loreal Paris Age Perfect Rosy Tone SPF 30 Renew and revive healthy tone Visibly younger-looking skin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New and more effective diagnostic procedures and targeted therapies against ACC
Trial: 26666942
Drug: Artemether-lumefantrine (six-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine (six-dose regimen)
Trial: 26667382
Drug: 12 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks of varenicline in combination with smoking cessation counseling
Trial: 26668134
Drug: Lenalidomide plus
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide plus low-dose dexamethasone (LenDex)
Trial: 26668712
Drug: Single-dose 13-valent
RxNorm normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose 13-valent pneumococcal conjugate vaccine (PCV13)
Trial: 26670630
Drug: Second PDT
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second PDT treatment
Trial: 26670630
Drug: High-density subthreshold
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-density subthreshold diode micropulse laser (HSML) therapy
Trial: 26670630
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment strategy (PDT + HSML)
Trial: 26670630
Drug: First half-dose
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First half-dose PDT treatment
Trial: 26672094
Drug: Isoglycemic intravenous
RxNorm normalized name: ioglycamic acid
DrugBank: Ioglycamic acid (DB13741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoglycemic intravenous glucose infusion
Trial: 26672987
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid supplementation (1.9 g/d EPA and 1.5 g/d DHA for six weeks)
Trial: 26674132
Drug: Combination immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination immunotherapy trial utilizing MEDI4736 and MEDI0680
Trial: 26674520
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg simvastatin daily for one year
Trial: 26674763
Drug: Controlled phytoene
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled phytoene diet (1-5 mg/d) for 42 days, with 3.2 mg (13)C-phytoene consumed on day 14.
Trial: 26675348
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human IL-7 (rhIL-7) administered as 3 subcutaneous doses per week.
Trial: 26675348
Drug: Injection site
RxNorm normalized name: Dual Injection Site
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection site reactions and hypersensitivity reaction to IL-7.
Trial: 26675779
Drug: Mothers taking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mothers taking vitamin D supplements
Trial: 26675779
Drug: Infant daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant daily intake through breast milk of vitamin D
Trial: 26676711
Drug: Nonoperative management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative management (24 hours inpatient observation with IV antibiotics, followed by 10 days of oral antibiotics)
Trial: 26678646
Drug: Antithrombotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic therapy (varied by physician discretion)
Trial: 26678860
Drug: Weighted combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weighted combination of symptom domains and endoscopic attributes
Trial: 26681111
Drug: HYD 20-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HYD 20-120 mg daily
Trial: 26681676
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg/day until progression or intolerance
Trial: 26681756
Drug: PZ-128 (0.01-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PZ-128 (0.01-2 mg/kg) administered by 1 to 2 hours continuous intravenous infusion
Trial: 26681756
Drug: PZ-128 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PZ-128 (0.5 mg/kg) with aspirin
Trial: 26681756
Drug: PZ-128 (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PZ-128 (0.5 mg/kg)
Trial: 26682038
Drug: Sublingual allergy
RxNorm normalized name: Callergy Clear
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual allergy immunotherapy tablet (GRAZAX®) plus standard treatment
Trial: 26682038
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus standard treatment
Trial: 26684198
Drug: Radiotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy and concomitant-adjuvant temozolomide chemotherapy
Trial: 26685770
Drug: Cyclophosphamide 50
RxNorm normalized name: cyclophosphamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 50 mg/kg
Trial: 26685770
Drug: Cyclophosphamide 100
RxNorm normalized name: cyclophosphamide 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 100 mg/kg
Trial: 26686256
Drug: Thalidomide at
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide at a starting dose of 50 mg/day, increased by 50 mg/day increments every 4 weeks up to a maximum of 200 mg/day if no response was seen.
Trial: 26687423
Drug: Azacitidine 75
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine 75 mg/m² once a day for days 1-5 of each 28-day cycle and lenalidomide (initially 50 mg for 10 days, later adjusted to 25 mg for 5 days)
Trial: 26687423
Drug: Azacitidine and
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine and lenalidomide combination
Trial: 26687796
Drug: (90)Y-DOTA-epratuzumab radioimmunotherapy
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (90)Y-DOTA-epratuzumab radioimmunotherapy at dose level 1 (2.5 mCi/m²)
Trial: 26687796
Drug: (90)Y-DOTA-epratuzumab radioimmunotherapy
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (90)Y-DOTA-epratuzumab radioimmunotherapy at dose level 2 (5.0 mCi/m²)
Trial: 26687796
Drug: (90)Y-DOTA-epratuzumab radioimmunotherapy
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (90)Y-DOTA-epratuzumab radioimmunotherapy at dose level 3 (7.5 mCi/m²)
Trial: 26687796
Drug: (90)Y-DOTA-epratuzumab radioimmunotherapy
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (90)Y-DOTA-epratuzumab radioimmunotherapy at dose level 4 (10.0 mCi/m²)
Trial: 26687958
Drug: Romidepsin 12
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin 12 mg/m(2) combined with CHOP (intravenous cyclophosphamide 750 mg/m(2), doxorubicin 50 mg/m(2), vincristine 1.4 mg/m(2) [maximum 2 mg], oral prednisone 40 mg/m(2))
Trial: 26687958
Drug: Romidepsin 10
RxNorm normalized name: romidepsin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Romidepsin 10 mg/m(2) combined with CHOP
Trial: 26687958
Drug: Romidepsin 8
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin 8 mg/m(2) combined with CHOP
Trial: 26687958
Drug: Romidepsin 12
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Romidepsin 12 mg/m(2) combined with CHOP
Trial: 26688485
Drug: Panobinostat 20
RxNorm normalized name: panobinostat 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobinostat 20 mg oral three times a week and bortezomib 1.3 mg/m² intravenous two times a week for 2 of 3 weeks for up to eight cycles.
Trial: 26688485
Drug: Panobinostat and
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panobinostat and bortezomib combination treatment
Trial: 26688487
Drug: PF-04449913 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04449913 at 80 mg
Trial: 26688487
Drug: PF-04449913 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04449913 at 600 mg
Trial: 26688487
Drug: PF-04449913 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04449913 (all doses)
Trial: 26688487
Drug: PF-04449913 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-04449913 at MTD (400 mg)
Trial: 26688487
Drug: Recommended phase
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommended phase 2 dose
Trial: 26688734
Drug: Walnut-included diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut-included diet (56 g providing 366 kcal per day)
Trial: 26693035
Drug: Enhanced External
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced External Counterpulsation (EECP) therapy, 260 mm Hg pressure, 60 minutes, 5 days a week for 7 weeks (35 sessions)
Trial: 26695065
Drug: Gadofosveset trisodium
RxNorm normalized name: Gadofosveset Trisodium
DrugBank: Gadofosveset trisodium (DB06705)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadofosveset trisodium injection using a dual-injection protocol (70% bolus / 30% slow infusion)
Trial: 26695065
Drug: Gadofosveset trisodium
RxNorm normalized name: Gadofosveset Trisodium
DrugBank: Gadofosveset trisodium (DB06705)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadofosveset trisodium injection using a dual-injection protocol (60% bolus / 40% slow infusion)
Trial: 26695065
Drug: Gadofosveset injection
RxNorm normalized name: gadofosveset
DrugBank: Gadofosveset trisodium (DB06705)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadofosveset injection optimized for lowest intravascular T1 time
Trial: 26698306
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of breath biomarkers with chest CT
Trial: 26698868
Drug: Hepatic arterial
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial infusion (HAI) of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) at doses of up to 300 mg/m(2) over 4 hours
Trial: 26698868
Drug: Hepatic arterial
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial infusion (HAI) of nab-paclitaxel over 1 hour
Trial: 26698868
Drug: Hepatic arterial
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic arterial infusion (HAI) of nab-paclitaxel
Trial: 26700485
Drug: TSH-suppressive LT4
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TSH-suppressive LT4 doses
Trial: 26700485
Drug: LT4 replacement
RxNorm normalized name: LT4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: LT4 replacement therapy
Trial: 26701919
Drug: Implant-supported therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-supported therapy
Trial: 26702094
Drug: VRC01 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC01 (single dose) in ART-untreated subjects
Trial: 26702094
Drug: VRC01 (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC01 (two infusions) in ART-treated subjects
Trial: 26702094
Drug: VRC01 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC01 (single dose) in ART-untreated subjects with plasma virus load <1000 copies/ml
Trial: 26702094
Drug: VRC01 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VRC01 (single dose) in ART-untreated subjects with baseline virus loads between 3000 and 30,000 copies
Trial: 26704148
Drug: Simeprevir 150
RxNorm normalized name: simeprevir 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeprevir 150 mg once daily + sofosbuvir 400 mg once daily for 12 weeks
Trial: 26704626
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg/day for 4 weeks